BIOCORP
13.4.2021 08:02:14 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French company specialized in the design, development and manufacturing of innovative medical devices, and Roche Diabetes Care France, a reference company in the support of patients with diabetes, announce the launch in France of Mallya, a medical device available in pharmacies. Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2 . Rechargeable via its USB port, Mallya is compatible with most disposable insulin pens1 . This innovation aims to simplify the daily life of patients with diabetes undergoing insulin therapy, and could help avoid errors or oversights.
Healthcare companies BIOCORP and Roche Diabetes Care France are finalizing their collaboration - announced last June - with the distribution of Mallya smart devices for insulin injection pens since the beginning of April. Manufactured in Clermont-Ferrand (France), this innovation for patients taking insulin is the first in its category to receive the CE-mark (medical device).
Reusable and compatible with 91%1 of disposable insulin pens, Mallya automatically collects insulin data (dose, date, time) and transfers it to the Gluci-Chek application developed by Roche Diabetes Care France, ensuring qualified information on which the patient can rely and the physician can then make decisions3 . With integration into the Roche Diabetes Care France digital ecosystem, patients benefit from solutions that lighten the mental burden of their disease, in a context where more than 750,000 people4 are treated with insulin injections in France (excluding insulin pumps).
“The commercial launch of Mallya represents an important milestone for BIOCORP. We are really proud to be leading it with Roche Diabetes Care France. Its leading position, its vast distribution network in pharmacies and the connection of our innovative device to its Gluci-Chek solution present undeniable benefits for all healthcare professionals but also and above all for diabetic patients looking for a better quality of life, a better comfort in the management and daily follow-up of their disease", said Eric Dessertenne, CEO of BIOCORP.
"For more than 40 years, we have been helping people with diabetes think less about the day-to-day management of their disease. We are committed to the autonomy and quality of life of patients with diabetes, empowering them to understand and act on their condition. This is precisely what Mallya allows, when integrated with our digital ecosystem for patients and healthcare professionals. We are currently the only company to offer a quality solution based on a CE marked medical device", added Frédéric Jacquey, President of Roche Diabetes Care France.
An innovation to improve the daily life and monitoring of diabetic patients on insulin
After the creation of insulin for therapeutic purposes 100 years ago, innovation continues in the field of diabetes, with the same ambition: to enable more and more patients to live better with their diabetes on a daily basis, a strong challenge for patients treated with insulin. To this end, Mallya collects and transfers insulin data in real time5 to their smartphone.
Once the device is installed, the patient selects and injects his or her insulin units as usual, with data transfer (date, time, selected dose) being done automatically. While 37%6 of patients with diabetes felt more anxious about their condition during the first Covid19 confinement, the simple and accurate2 Mallya device makes it easier for them to follow the evolution of their disease. It could thus contribute to more serenity, more security and less error or forgetfulness in taking their treatment.
Shared with healthcare professionals3 through the dedicated Roche Diabetes Care Platform, accurate and comprehensive insulin data2 allows them to monitor - face-to-face or remotely - the progress of their patients' disease, refine their interpretation and help adjust treatment decisions.
A device integrated into a global solution to facilitate diabetes management
The device enhances Roche Diabetes Care France's digital ecosystem for integrated personalized diabetes management. This solution was previously based on three elements: connected blood glucose meters (Accu-Chek® Mobile, Accu-Chek® Guide), the Gluci-Chek application and the Roche Diabetes Care platform dedicated to healthcare professionals. Mallya is adding insulin data for more comprehensive patient monitoring.
Used regularly by more than 60,000 diabetic patients in France, this smartphone application combines three major functionalities for personalized diabetes management: a carbohydrate calculation tool with a visualization of the portions on the plate, a self-monitoring of blood glucose diary and a graphic visualization of glycemic results.
Once Mallya is connected to Gluci-Chek, the patient no longer has to manually report his or her insulin doses, as the data is automatically displayed in the patient's blood glucose logbook, for any compatible insulin pen1 . In a context where French people are confined again and where 58%3 of patients with diabetes did not feel they had received any particular help during their first confinement, this connected device can provide real close monitoring.
ABOUT ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been pioneering solutions to meet the needs of patients and healthcare professionals: medical devices (blood glucose meters, auto-pickers, insulin pumps), digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals) and services (information and therapeutic education support). Through the implementation of a global solution connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for integrated Personalized Diabetes Management (iPDM), with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr .
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com .
1 The Mallya medical device is compatible with Solostar pens (ref. 9828648001), FlexPen pens (ref. 9832360001) and KwikPen pens (ref. 9827587001) with the exception of Junior KwikPen pens as of January 1, 2021. Calculation of market share for disposable insulin pens from Caisse Nationale d'Assurance Maladie. Open Medic 2019 database.
2 99% according to Mallya IFU version 6. Caution: some external factors may affect the accuracy of dose measurement or data transfer.
3 If the patient decides to share his/her data.
4 Source: IQVIA - LTD : Analysis of BGMin real life – Meters and strips markets - CMA February 2020 - Patients and volume.
5 As soon as Bluetooth is activated.
6 Online study conducted by CSA Research for Roche Diabetes Care France from May 18th to 27th, 2020, with 504 diabetic patients (101 type1 diabetic patients and 403 type2 diabetic patients)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005837/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New NEURA Gym with RWTH Aachen: NEURA Robotics Expands its Global Training Network for Physical AI22.7.2026 09:10:00 CEST | Press release
NEURA Gym RWTH Aachen to open by end of 2026Ten NEURA Gyms under development, five operational by end of 2026 across Europe, the United States and ChinaIndustry partners gain access to the world’s first open infrastructure for training and deploying Physical AI NEURA Robotics ("NEURA"), the pioneer in cognitive robotics and creator of the Neuraverse, today announces a new partnership with RWTH Aachen University for the establishment of NEURA Gym RWTH Aachen. This continues the global rollout of NEURA Gyms, a worldwide network of purpose-built Physical AI training facilities that address the most significant barrier to intelligent robotics: the scarcity of real-world training data. The global rollout is backed by NEURA's Series C financing of up to $1.4 billion, the largest ever raised by a full-stack robotics company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721136838/en/ New NEURA Gym with RWTH Aachen: NEURA Roboti
Specright Launches Automated PPWR Declaration of Conformity Reporting22.7.2026 06:00:00 CEST | Press release
New capability automates PPWR Declaration of Conformity reporting ahead of the EU's August 2026 deadline. Specright™, the leader in AI-powered Specification Data Management™ (SDM) and modern Product Lifecycle Management (PLM), today announced a new Declaration of Conformity (DoC) reporting capability that automates a core requirement of the EU's Packaging and Packaging Waste Regulation (PPWR). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721689027/en/ Specright's new capability automates PPWR Declaration of Conformity reporting ahead of the EU's August 2026 deadline. Companies placing packaged goods on the EU market must produce a signed DoC starting August 12, 2026, covering PPWR Articles 5 through 12 — substance restrictions, recyclability, recycled content, minimization, reusability, and labeling. For most brands, that documentation is scattered across suppliers and spreadsheets, turning routine filings into monthslo
MediaCo Appoints Brian Fisher as President21.7.2026 22:15:00 CEST | Press release
Leadership Appointments Align Executive Team to Support Company's Next Phase of Growth MediaCo Holding Inc. (Nasdaq: MDIA) today announced executive leadership appointments that align the Company's leadership structure to support its long-term growth strategy. Effective immediately, Brian Fisher has been appointed President of MediaCo. Albert Rodriguez will continue to serve as Chief Executive Officer, focusing on the Company's long-term strategy, growth initiatives and shareholder value, while Fisher assumes responsibility for leading the Company's day-to-day operations and execution. The Company also announced that Roberto Castro has been appointed Interim Chief Financial Officer and Interim Treasurer, overseeing the Finance organization while a search is conducted for a permanent Chief Financial Officer. "MediaCo has built tremendous momentum, and these leadership appointments position us well for our next phase of growth," said Albert Rodriguez, Chief Executive Officer of MediaCo.
Footprint Expands Into PE-Free Cups, Bringing a Proven, Recyclable and Home-Compostable Alternative to Plastic-Lined Paper Cups Into Production21.7.2026 18:00:00 CEST | Press release
Move strengthens Footprint’s European manufacturing platform and supports growing demand for practical alternatives to single-use plastic Footprint, a materials science and technology company focused on eliminating single-use plastics, today announced it has acquired a recyclable, home-compostable, polyethylene (PE)-free hot and cold cup platform from Transcend Packaging, along with next-generation paper lid and straw solutions. Transcend Packaging is a European company focused on innovation in sustainable packaging solutions. Together, the cup, lid, and straw expand Footprint’s portfolio with a proven solution for the global cup market. Footprint will begin scaling its new PE-free solution through its Poland facility as the company expands across Europe, with North America to follow. As operations ramp in Poland, Footprint will work with Transcend through a manufacturing partnership to support customer continuity across Europe and meet growing demand for practical alternatives to plas
Spectro Cloud Launches PaletteAI Inference Launchpad to Reduce Enterprise Token Costs by up to 70%21.7.2026 16:00:00 CEST | Press release
New turnkey, locally managed PaletteAI Inference Launchpad helps enterprises control token costs with local-first inference, while expanded PaletteAI support for AMD gives customers more choice across GPUs, models and AI infrastructure stacks. Spectro Cloud, a leading provider of AI infrastructure management software, today launched PaletteAI Inference Launchpad, a turnkey, locally managed solution designed to help enterprises reduce token costs by as much as 70% and run AI inference closer to their data, applications and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721597271/en/ The company also announced expanded PaletteAI support for AMD-powered AI infrastructure, including AMD GPUs, AMD GPU Operator, ROCm™ runtime, and the AMD enterprise AI reference stack — including AMD-optimized models from the AMD Inference Microservices (AIMs) catalog. Together, the announcements expand PaletteAI as one platform for prod
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom